| 12/05/2018 |
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2019 (IFRS) |
| 11/09/2018 |
FY2019/3 H1, Supplementary Material(Apr.1 to Sep.30 2018) |
| 11/09/2018 |
FY2019/3 H1, Presentation (Apr.1 to Sep.30 2018) |
| 08/30/2018 |
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March, 2019 |
| 08/08/2018 |
Year Ending March 31, 2019 Results of 1st Quarter Settlement of Accounts Supplementary Material(Apr.1 to Jun.30 2018) |
| 07/10/2018 |
Notice regarding business alliance with Sunward Pharmaceutical Pte. Ltd. (Singapore) |
| 06/18/2018 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2018 (IFRS) |
| 06/18/2018 |
Etanercept BS Licensing Agreement |
| 05/14/2018 |
Year Ended March 31, 2018 Results Settlement of Accounts Supplementary Material (Apr.1 2017 to Mar.31 2018) |
| 05/14/2018 |
FY2017, ended March 2018 |
| 04/17/2018 |
Announcement of completion of new production facility by Aprogen Biologics Inc. |
| 03/29/2018 |
Strategic Alliance Agreement for the Generic Business of Nichi-Iko Pharmaceutical Co., Ltd. and Eisai Co. |
| 03/28/2018 |
EISAI AND NICHI-IKO PHARMACEUTICAL ENTER INTO STRATEGIC ALLIANCE AGREEMENT |
| 02/22/2018 |
Consolidated Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31,2018 |
| 02/07/2018 |
Year Ending March 31, 2018 Results of 3rd Quarter Settlement of Accounts Supplementary Material (Apr.1 to Dec.31 2017) |
